Skip to main content
Erschienen in: Tumor Biology 6/2014

01.06.2014 | Research Article

Aberrant BLID expression is associated with breast cancer progression

verfasst von: Xiaoyan Li, Peng Su, Xianqiang Liu, Xiangnan Kong, Xin Zhang, Hongyu Zhang, Qifeng Yang

Erschienen in: Tumor Biology | Ausgabe 6/2014

Einloggen, um Zugang zu erhalten

Abstract

In our previous study, we have found that BH3-like motif containing, cell death inducer (BLID) was a tumor suppressor in breast cancer, and its downregulation was correlated with both poor disease-free and overall survival. In the present study, we aimed to explore the possible role of BLID in breast cancer progression. We found that BLID was strongly expressed in all normal breast tissues, and it became lower and wreaker gradually in the progression from normal, UDH (usual ductal hyperplasia), ADH (atypical ductal hyperplasia), and DCIS (ductal carcinoma in situ) to breast cancer. Statistical analysis demonstrated significant different BLID expressions between proliferative and cancerous breast lesions. Our data suggested that loss of BLID may contribute to the progression of intraductal proliferation lesions to breast cancer. Our finding gives a new clue that BLID might be a potential indicator for progression of breast cancer in the future.
Literatur
1.
3.
Zurück zum Zitat Bai M, Agnantis NJ, Kamina S, Demou A, Zagorianakou P, Katsaraki A, et al. In vivo cell kinetics in breast carcinogenesis. Breast Cancer Res. 2001;3:276–83.PubMedCentralCrossRefPubMed Bai M, Agnantis NJ, Kamina S, Demou A, Zagorianakou P, Katsaraki A, et al. In vivo cell kinetics in breast carcinogenesis. Breast Cancer Res. 2001;3:276–83.PubMedCentralCrossRefPubMed
4.
Zurück zum Zitat Ellis IO. Intraductal proliferative lesions of the breast: morphology, associated risk and molecular biology. Mod Pathol. 2010;23 Suppl 2:S1–7.CrossRefPubMed Ellis IO. Intraductal proliferative lesions of the breast: morphology, associated risk and molecular biology. Mod Pathol. 2010;23 Suppl 2:S1–7.CrossRefPubMed
5.
Zurück zum Zitat Mommers EC, Poulin N, Sangulin J, Meijer CJ, Baak JP, van Diest PJ. Nuclear cytometric changes in breast carcinogenesis. J Pathol. 2001;193:33–9.CrossRefPubMed Mommers EC, Poulin N, Sangulin J, Meijer CJ, Baak JP, van Diest PJ. Nuclear cytometric changes in breast carcinogenesis. J Pathol. 2001;193:33–9.CrossRefPubMed
6.
Zurück zum Zitat Page DL, Dupont WD. Anatomic indicators (histologic and cytologic) of increased breast cancer risk. Breast Cancer Res Treat. 1993;28:157–66.CrossRefPubMed Page DL, Dupont WD. Anatomic indicators (histologic and cytologic) of increased breast cancer risk. Breast Cancer Res Treat. 1993;28:157–66.CrossRefPubMed
7.
Zurück zum Zitat Broustas CG, Gokhale PC, Rahman A, Dritschilo A, Ahmad I, Kasid U. Brcc2, a novel bh3-like domain-containing protein, induces apoptosis in a caspase-dependent manner. J Biol Chem. 2004;279:26780–8.CrossRefPubMed Broustas CG, Gokhale PC, Rahman A, Dritschilo A, Ahmad I, Kasid U. Brcc2, a novel bh3-like domain-containing protein, induces apoptosis in a caspase-dependent manner. J Biol Chem. 2004;279:26780–8.CrossRefPubMed
8.
Zurück zum Zitat Cavalli LR, Santos SC, Broustas CG, Rone JD, Kasid UN, Haddad BR. Assignment of the BLID gene to 11q24.1 by fluorescence in situ hybridization. Cancer Genet Cytogenet. 2008;186:120–1.CrossRefPubMed Cavalli LR, Santos SC, Broustas CG, Rone JD, Kasid UN, Haddad BR. Assignment of the BLID gene to 11q24.1 by fluorescence in situ hybridization. Cancer Genet Cytogenet. 2008;186:120–1.CrossRefPubMed
9.
Zurück zum Zitat Li X, Kong X, Wang Y, Yang Q. Brcc2 inhibits breast cancer cell growth and metastasis in vitro and in vivo via downregulating AKT pathway. Cell Death Dis. 2013;4:e757.PubMedCentralCrossRefPubMed Li X, Kong X, Wang Y, Yang Q. Brcc2 inhibits breast cancer cell growth and metastasis in vitro and in vivo via downregulating AKT pathway. Cell Death Dis. 2013;4:e757.PubMedCentralCrossRefPubMed
10.
Zurück zum Zitat Broustas CG, Ross JS, Yang Q, Sheehan CE, Riggins R, Noone AM, et al. The proapoptotic molecule BLID interacts with Bcl-XL and its downregulation in breast cancer correlates with poor disease-free and overall survival. Clin Cancer Res. 2010;16:2939–48.CrossRefPubMed Broustas CG, Ross JS, Yang Q, Sheehan CE, Riggins R, Noone AM, et al. The proapoptotic molecule BLID interacts with Bcl-XL and its downregulation in breast cancer correlates with poor disease-free and overall survival. Clin Cancer Res. 2010;16:2939–48.CrossRefPubMed
11.
Zurück zum Zitat Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, et al. Revision of the american joint committee on cancer staging system for breast cancer. J Clin Oncol. 2002;20:3628–36.CrossRefPubMed Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, et al. Revision of the american joint committee on cancer staging system for breast cancer. J Clin Oncol. 2002;20:3628–36.CrossRefPubMed
12.
Zurück zum Zitat Li X, Xu B, Moran MS, Zhao Y, Su P, Haffty BG, et al. 53 bp1 functions as a tumor suppressor in breast cancer via the inhibition of nf-kappab through mir-146a. Carcinogenesis. 2012;33:2593–600.CrossRefPubMed Li X, Xu B, Moran MS, Zhao Y, Su P, Haffty BG, et al. 53 bp1 functions as a tumor suppressor in breast cancer via the inhibition of nf-kappab through mir-146a. Carcinogenesis. 2012;33:2593–600.CrossRefPubMed
13.
14.
Zurück zum Zitat Ganesan K, Acharya UR, Chua CK, Min LC, Abraham KT, Ng KH. Computer-aided breast cancer detection using mammograms: a review. IEEE Rev Biomed Eng. 2013;6:77–98.CrossRefPubMed Ganesan K, Acharya UR, Chua CK, Min LC, Abraham KT, Ng KH. Computer-aided breast cancer detection using mammograms: a review. IEEE Rev Biomed Eng. 2013;6:77–98.CrossRefPubMed
16.
Zurück zum Zitat Esserman LJ, Shieh Y, Rutgers EJ, Knauer M, Retel VP, Mook S, et al. Impact of mammographic screening on the detection of good and poor prognosis breast cancers. Breast Cancer Res Treat. 2011;130:725–34.CrossRefPubMed Esserman LJ, Shieh Y, Rutgers EJ, Knauer M, Retel VP, Mook S, et al. Impact of mammographic screening on the detection of good and poor prognosis breast cancers. Breast Cancer Res Treat. 2011;130:725–34.CrossRefPubMed
17.
Zurück zum Zitat Skomedal H, Helland A, Kristensen GB, Holm R, Borresen-Dale AL. Allelic imbalance at chromosome region 11q23 in cervical carcinomas. Eur J Cancer. 1999;35:659–63.CrossRefPubMed Skomedal H, Helland A, Kristensen GB, Holm R, Borresen-Dale AL. Allelic imbalance at chromosome region 11q23 in cervical carcinomas. Eur J Cancer. 1999;35:659–63.CrossRefPubMed
18.
Zurück zum Zitat Gentile M, Ahnstrom M, Schon F, Wingren S. Candidate tumour suppressor genes at 11q23–q24 in breast cancer: evidence of alterations in pig8, a gene involved in p53-induced apoptosis. Oncogene. 2001;20:7753–60.CrossRefPubMed Gentile M, Ahnstrom M, Schon F, Wingren S. Candidate tumour suppressor genes at 11q23–q24 in breast cancer: evidence of alterations in pig8, a gene involved in p53-induced apoptosis. Oncogene. 2001;20:7753–60.CrossRefPubMed
19.
Zurück zum Zitat Tassano E, Acquila M, Tavella E, Micalizzi C, Panarello C, Morerio C. Microrna-125b-1 and BLID upregulation resulting from a novel IGH translocation in childhood b-cell precursor acute lymphoblastic leukemia. Genes Chromosom Cancer. 2010;49:682–7.CrossRefPubMed Tassano E, Acquila M, Tavella E, Micalizzi C, Panarello C, Morerio C. Microrna-125b-1 and BLID upregulation resulting from a novel IGH translocation in childhood b-cell precursor acute lymphoblastic leukemia. Genes Chromosom Cancer. 2010;49:682–7.CrossRefPubMed
20.
Zurück zum Zitat Gentile M, Olsen K, Dufmats M, Wingren S. Frequent allelic losses at 11q24.1–q25 in young women with breast cancer: association with poor survival. Br J Cancer. 1999;80:843–9.PubMedCentralCrossRefPubMed Gentile M, Olsen K, Dufmats M, Wingren S. Frequent allelic losses at 11q24.1–q25 in young women with breast cancer: association with poor survival. Br J Cancer. 1999;80:843–9.PubMedCentralCrossRefPubMed
21.
Zurück zum Zitat Chunder N, Mandal S, Roy A, Roychoudhury S, Panda CK. Analysis of different deleted regions in chromosome 11 and their interrelations in early- and late-onset breast tumors: association with cyclin d1 amplification and survival. Diagn Mol Pathol. 2004;13:172–82.CrossRefPubMed Chunder N, Mandal S, Roy A, Roychoudhury S, Panda CK. Analysis of different deleted regions in chromosome 11 and their interrelations in early- and late-onset breast tumors: association with cyclin d1 amplification and survival. Diagn Mol Pathol. 2004;13:172–82.CrossRefPubMed
22.
Zurück zum Zitat Climent J, Dimitrow P, Fridlyand J, Palacios J, Siebert R, Albertson DG, et al. Deletion of chromosome 11q predicts response to anthracycline-based chemotherapy in early breast cancer. Cancer Res. 2007;67:818–26.CrossRefPubMed Climent J, Dimitrow P, Fridlyand J, Palacios J, Siebert R, Albertson DG, et al. Deletion of chromosome 11q predicts response to anthracycline-based chemotherapy in early breast cancer. Cancer Res. 2007;67:818–26.CrossRefPubMed
23.
Zurück zum Zitat Cavalli LR, Noone AM, Makambi KH, Rone JD, Kasid UN, Haddad BR. Frequent loss of the BLID gene in early-onset breast cancer. Cytogenet Genome Res. 2011;135:19–24.PubMedCentralCrossRefPubMed Cavalli LR, Noone AM, Makambi KH, Rone JD, Kasid UN, Haddad BR. Frequent loss of the BLID gene in early-onset breast cancer. Cytogenet Genome Res. 2011;135:19–24.PubMedCentralCrossRefPubMed
Metadaten
Titel
Aberrant BLID expression is associated with breast cancer progression
verfasst von
Xiaoyan Li
Peng Su
Xianqiang Liu
Xiangnan Kong
Xin Zhang
Hongyu Zhang
Qifeng Yang
Publikationsdatum
01.06.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 6/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-1710-x

Weitere Artikel der Ausgabe 6/2014

Tumor Biology 6/2014 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.